Trial Profile
A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Lemborexant (Primary) ; Suvorexant; Zolpidem
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Eisai Inc
- 24 Jun 2022 Results assessing abuse potential of Lemborexant published in the Journal of Clinical Psychopharmacology
- 24 Jun 2022 Results assessing acute cognitive effects of Lemborexant published in the Journal of Clinical Psychopharmacology
- 30 Jul 2018 Status changed from recruiting to completed.